Most pigmentation treatments fail because they target only one step of melanogenesis

Most pigmentation treatments fail because they target only one step of melanogenesis.

Hydroquinone (HQ) is still considered the gold standard for treating hyperpigmentation. It works—there is no debate about that.

However, long-term use is where the concern begins. Prolonged or unsupervised use can lead to complications such as exogenous ochronosis, skin atrophy, and potential local or systemic side effects. In my view, hydroquinone should be treated as a short-term medical tool, not a long-term skincare strategy.

Melanin production, or melanogenesis, is not a single-step process. It is a multi-stage pathway:

1.	Activation – triggered by UV exposure, inflammation (like acne), and hormonal signals

2.	Synthesis – tyrosinase converts tyrosine into melanin

3.	Transfer – melanin is transferred to surrounding skin cells

4.	Accumulation – pigmented cells remain on the surface

Most treatments fail because they target only one part of this pathway.

Effective pigmentation management requires intervention at multiple levels simultaneously.

A more balanced approach focuses on regulating this pathway:

• Reduce activation: sunscreen (zinc oxide, iron oxides), antioxidants, anti-inflammatory agents

• Inhibit synthesis: ingredients like kojic acid, arbutin, licorice extract, retinoids

• Reduce transfer: niacinamide, peptides

• Remove pigment: controlled exfoliation (AHAs, retinoids)

The shift in modern skincare is moving from “removing pigment” to “controlling the pathway.”

Hydroquinone can give quick results, but without addressing the full process, pigmentation often returns.

If you are treating pigmentation, think in layers: sunscreen + inhibitor + turnover. Not a single product.

As a formulator, I see this mistake very often.